会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 84. 发明申请
    • METHOD FOR PRODUCING PROTEIN COMPOSITION, AND PROTEIN COMPOSITION
    • US20180055958A1
    • 2018-03-01
    • US15556765
    • 2016-03-09
    • SANYO CHEMICAL INDUSTRIES, LTD.
    • Satoshi SOMAMOTOShingo KAWABATA
    • A61L2/08C07K1/06C07K1/26
    • A61L2/08A61L2202/20C07K1/00C07K1/061C07K1/26C07K14/78
    • The present invention aims to provide a method for producing a protein composition, the method being capable of suppressing changes such as degradation and denaturation of a protein which occur when a highly hydrophilic protein or a protein that undergoes denaturation by complete removal of water is irradiated with radiation. The present invention provides a method for producing a protein composition containing a protein (A), a radical scavenger (RS), and at least one hydrogen-bond-formable compound (HC) selected from the group consisting of amino acids, peptides, and proteins other than the protein (A), the method including a sterilization step of radiosterilizing an unsterilized protein composition, wherein the unsterilized protein composition contains the protein (A), the radical scavenger (RS), and the hydrogen-bond-formable compound (HC), the protein (A) contains at least one functional group selected from the group consisting of sulfide, amide, hydroxyl, amino, and carboxyl groups, the hydrogen-bond-formable compound (HC) contains at least one functional group selected from the group consisting of sulfide, amide, hydroxyl, amino, and carboxyl groups, the at least one functional group in the protein (A) is capable of binding to the at least one functional group in the hydrogen-bond-formable compound (HC) via a hydrogen bond, the unsterilized protein composition has a water content of 0 to 30% by weight based on the weight of the unsterilized protein composition, a weight ratio of the radical scavenger (RS) to the protein (A) in the unsterilized protein composition [radical scavenger (RS)/protein (A)] is 0.01 to 1.0, and a molar ratio of a total molar number of functional groups in the hydrogen-bond-formable compound (HC) to a total molar number of functional groups in the protein (A) in the unsterilized protein composition [the total molar number of functional groups in the hydrogen-bond-formable compound (HC)/the total molar number of functional groups in the protein (A)] is 0.01 to 0.50.
    • 88. 发明申请
    • COMPOSITION FOR FORMING SEMI-RIGID POLYURETHANE FOAM
    • 用于形成半刚性聚氨酯泡沫的组合物
    • US20160311962A1
    • 2016-10-27
    • US15105134
    • 2014-12-16
    • SANYO CHEMICAL INDUSTRIES, LTD.
    • Shunsuke Kinoshita
    • C08G18/48C08G18/18C08G18/76
    • The purpose of the present invention is to provide a composition for forming a semi-rigid polyurethane foam that has low hardness and a resilient feel, has excellent moldability and curability even when made lightweight (made thin), and is suitable for use as an automobile interior material. The present invention is a composition for forming a semi-rigid polyurethane foam that comprises: a polyol mixture (P) that contains a specific polyol (the composition) (A), a water-containing foaming agent (C), and a catalyst (D); and a polyisocyanate component (B). The content of foaming agent (C) is 1.5-2.5 wt % based on the total weight of (A).
    • 本发明的目的是提供一种用于形成具有低硬度和弹性的半硬质聚氨酯泡沫的组合物,即使制成轻质(制成薄)也具有优异的成型性和固化性,并且适合用作汽车 内饰材料 本发明是一种用于形成半硬质聚氨酯泡沫的组合物,其包含:含有特定多元醇(组合物)(A)的多元醇混合物(P),含水发泡剂(C)和催化剂 D); 和多异氰酸酯组分(B)。 发泡剂(C)的含量相对于(A)的总重量为1.5〜2.5重量%。
    • 90. 发明授权
    • Proteinaceous protease inhibitor and protein solution and detergent composition containing it
    • US09403897B2
    • 2016-08-02
    • US14347298
    • 2012-10-05
    • Sanyo Chemical Industries, Ltd.
    • Miki KusanoFusamitsu Yanagihara
    • C11D9/00A61K38/48C07K14/81C11D3/386
    • C07K14/81C11D3/386C11D3/38618C11D3/38663
    • An object of the present invention is to provide proteinaceous protease inhibitors with moderate inhibitory activity. A proteinaceous protease inhibitor of the present invention includes an amino acid sequence (Y) or an amino acid sequence (Y′), the amino acid sequence (Y) being different from the amino acid sequence (A) of a proteinaceous protease inhibitor (BC), represented by SEQ ID NO:1, by one to eight amino acid replacements with amino acids different from replaced amino acids, the amino acid sequence (Y′) having at least 80% homology to the amino acid sequence (Y), wherein the proteinaceous protease inhibitor satisfies at least one of the following conditions (1) to (8): (1) the amino acid residue at a position corresponding to residue 12 of the amino acid sequence (A) in the amino acid sequence (Y) or (Y′) is an amino acid (X1) defined below; (2) the amino acid residue at a position corresponding to residue 38 of the amino acid sequence (A) in the amino acid sequence (Y) or (Y′) is an amino acid (X2) defined below; (3) the amino acid residue at a position corresponding to residue 48 of the amino acid sequence (A) in the amino acid sequence (Y) or (Y′) is an amino acid (X3) defined below; (4) the amino acid residue at a position corresponding to residue 50 of the amino acid sequence (A) in the amino acid sequence (Y) or (Y′) is an amino acid (X4) defined below; (5) the amino acid residue at a position corresponding to residue 51 of the amino acid sequence (A) in the amino acid sequence (Y) or (Y′) is an amino acid (X5) defined below; (6) the amino acid residue at a position corresponding to residue 52 of the amino acid sequence (A) in the amino acid sequence (Y) or (Y′) is an amino acid (X6) defined below; (7) the amino acid residue at a position corresponding to residue 53 of the amino acid sequence (A) in the amino acid sequence (Y) or (Y′) is an amino acid (X7) defined below; (8) the amino acid residue at a position corresponding to residue 70 of the amino acid sequence (A) in the amino acid sequence (Y) or (Y′) is an amino acid (X8) defined below: (X1): any of amino acids (X0) other than Glu (X2): any of the amino acids (X0) other than Val and Ile (X3): any of the amino acids (X0) other than Met (X4): any of the amino acids (X0) other than Tyr (X5): any of the amino acids (X0) other than Arg (X6): any of the amino acids (X0) other than Ile (X7): any of the amino acids (X0) other than Asp (X8): any of the amino acids (X0) other than Arg; and (X0): Ala, Arg, Asn, Asp, Cys, Gly, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.